Posted by Michael Wonder on 30 Mar 2021
Moleculin receives FDA approval of fast track designation for annamycin in the treatment of sarcoma lung metastases
30 March 2021 - Moleculin Biotech today announced that the U.S. FDA has approved its request for fast track designation for its drug, Annamycin, for the treatment of soft tissue sarcoma lung metastases.
Annamycin is a "next generation" anthracycline that has recently been shown in animal models to accumulate in the lungs at up to 30 fold the level of doxorubicin.
